The bill aims to improve the availability and accessibility of necessary medical tests, particularly for conditions that may benefit significantly from genetic insight. By doing this, it hopes to enhance the accuracy of diagnoses and treatment plans for individuals, especially children with rare diseases. Furthermore, the creation of tax credits for businesses offering insurance coverage under the Employee Retirement Income Security Act (ERISA) is intended to incentivize these businesses, thereby potentially increasing access to health insurance among employees.
Summary
Senate Bill 828 proposes significant changes to the health care landscape in Missouri, particularly in relation to medical testing and tax incentives for businesses that provide health insurance. One of the key features of the bill is the repeal of certain existing sections regarding medical testing and the introduction of new provisions aimed at enhancing genetic and biomarker testing. The bill mandates that health benefit plans cover biomarker testing without age restrictions, recognizing the emerging importance of genomics in diagnosing and managing health conditions.
Contention
Notably, the projected fiscal implications of these changes are a point of contention. The tax credits are capped at $20 million annually, a figure that some legislators worry could strain the state budget. Additionally, while supporters argue that extending coverage for biomarker testing will lead to better healthcare outcomes, critics question the adequacy of funding and the bill's implications for long-term healthcare costs. There is also concern about whether the expansion of testing will be matched by necessary healthcare infrastructure and provider capacity.